|
|
Post by RN69 on Aug 27, 2021 13:33:41 GMT
|
|
|
|
Post by ratioetfides on Aug 27, 2021 19:04:28 GMT
Thank you for sharing.
This is more evidence ADE (antibody dependent enhancement) is not a major concern with these strains/variants of SARS-CoV-2.
|
|
|
|
Post by RN69 on Aug 27, 2021 23:52:19 GMT
My grasp on the complex issue of ADE is really basic. I know that our bodies set up a line of defense against invasion of foreign microbes by sending in cells using phagocytosis to engulf and destroy them. But if a virus isn't neutralized (for variety of reasons ) it can cause viral escape and enhanced infection. So the phagocytosis that should kill the invader may actually help it to replicate and overwhelm the immune system. One article that I read described it thus: 'The virus “deceives” the process of phagocytosis of immune cells and uses the host's antibodies as a Trojan horse.' to enter into the hosts cells. That's my bare bones understanding of antibody dependant enhancement and it may be lacking in details or it maybe totally off of the mark. The following explains how the mAb (monoclonal antibody) sotrovimab works. Not my words and are excerpts from an article that I read. It isn't a cure all and the effects don't last. Not everyone can benefit from getting mAb and in some cases it could be detrimental. Advice from your own physician is essential. [Sotrovimab works by binding to the spike protein on the outside of the COVID-19 virus. By binding to the spike protein, sotrovimab can block the virus from attaching to and entering human cells. This stops the virus replicating in the body. The US Food and Drug Administration has approved sotrovimab for emergency use as an intravenous injection to treat COVID-19 patients at high risk of progressing to severe disease. Sotrovimab can be given as soon as someone receives a positive test result or within ten days of getting COVID-19 symptoms.] Below is brief article that explains mAb therapy. www.houstonmethodist.org/blog/articles/2021/jan/what-is-monoclonal-antibody-therapy-and-who-is-eligible-to-receive-it/ |
|
joeg
Full Member
Posts: 135
|
Post by joeg on Oct 16, 2021 2:55:28 GMT
This is from a recent French computer modeling study warning about an increase in risk for antibody dependent enhancement (ADE). They use the ADE-related term, "facilitating antibodies" in contrast to the protective "neutralizing antibodies". Notice their suggestion that we get new, safer vaccines. "our data suggest that the balance between neutralizing and facilitating antibodies in vaccinated individuals is in favor of neutralization for the original Wuhan/D614G strain. However, in the case of the Delta variant, neutralizing antibodies have a decreased affinity for the spike protein, whereas facilitating antibodies display a strikingly increased affinity. Thus, ADE may be a concern for people receiving vaccines based on the original Wuhan strain spike sequence (either mRNA or viral vectors). Under these circumstances, second generation vaccines with spike protein formulations lacking structurally-conserved ADE-related epitopes should be considered." www.ncbi.nlm.nih.gov/pmc/articles/PMC8351274/So notice their concern about a safe and effective balance between neutralization and facilitation. I've never heard that ADE is an issue with the monoclonal antibodies but considering the government's position on noble lies I would not be shocked if it is a theoretical possibility. Since MAB therapy is short term I'd be surprised if ADE is an issue. This is from Children's Hospital Philly on ADE
Antibodies that prevent entry into cells are called neutralizing antibodies. Many vaccines work by inducing neutralizing antibodies. However, not all antibody responses are created equal. Sometimes antibodies do not prevent cell entry and, on rare occasions, they may actually increase the ability of a virus to enter cells and cause a worsening of disease through a mechanism called antibody-dependent enhancement (ADE).
ADE occurs when the antibodies generated during an immune response recognize and bind to a pathogen, but they are unable to prevent infection. Instead, these antibodies act as a “Trojan horse,” allowing the pathogen to get into cells and exacerbate the immune response.www.chop.edu/centers-programs/vaccine-education-center/vaccine-safety/antibody-dependent-enhancement-and-vaccines |
|
